Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals announced an upcoming webinar to discuss its Quarterly Activity Report and the increasing launch momentum of its lead product, Sofdra. The webinar will also address how the company’s financial position supports Sofdra’s path to profitability, indicating a strategic focus on solidifying its market presence and ensuring sustainable growth.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix, focusing on innovative treatments for dermatological conditions. Its primary product, Sofdra, is a topical gel approved by the FDA for treating primary axillary hyperhidrosis, offering a novel solution for a condition with limited treatment options.
Average Trading Volume: 15,556,483
Technical Sentiment Signal: Sell
Current Market Cap: A$333.4M
See more data about BOT stock on TipRanks’ Stock Analysis page.